| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.5 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.036 | 0.5 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |